Includes bibliographical references and index.

Print version record and CIP data provided by publisher.

Title page; Table of Contents; List of contributors; Foreword; Introduction; Declaration of commercial interest; References; Section 1: Transplantation in lymphomas; Chapter 1: Lymphoma and transplantation: historical perspective; Brief history of hematopoietic cell transplantation; History of autologous HCT in non-Hodgkin lymphoma; History of autologous HCT in Hodgkin lymphoma; History of allogeneic HCT in lymphoma; General historical considerations; References; Chapter 2: Lymphoma: working committee and data reporting after transplantation in lymphoma; Introduction; Registry structure

Data reportingOvercoming challenges to data reporting; Data quality; The Lymphoma Working Committee; Statistical methods; Selected examples from the CIBMTR Lymphoma Committee; Value for young investigators; Value for public and other stakeholders; Conclusion; References; Chapter 3: Use of transplantation in lymphoma: adults; Introduction; Hodgkin lymphoma; Non-Hodgkin lymphoma; Prognostic tools; Maintenance therapies; Novel therapies; Conclusions; References; Chapter 4: Hematopoietic stem cell transplantation for lymphoma in children, adolescents, and young adults; Introduction

Principles of autologous and allogeneic HSCT in pediatric lymphomasHodgkin lymphoma; Lymphoblastic lymphoma; Anaplastic large-cell lymphoma; Mature B-cell lymphomas: Burkitt lymphoma, diffuse large B-cell lymphoma, and primary mediastinal B-cell lymphoma; Future directions; Conclusions; References; Chapter 5: Preparative regimens for lymphoma: autologous hematopoietic stem cell transplantation; Rationale for chemotherapy dose intensification for disease eradication; Traditional preparative regimens; Incorporation of monoclonal antibodies in autologous HCT preparative regimens

Novel agents used in preparative regimensFuture directions; References; Chapter 6: Preparative regimens for lymphoma: allogeneic hematopoietic stem cell transplantation; Introduction; Myeloablative conditioning regimens for lymphomas; Reduced-intensity conditioning regimens; Incorporating monoclonal antibodies in preparative regimens for allo-HCT; Alternative donor sources; Discussion and future direction; References; Chapter 7: Pretransplantation evaluation, comorbidities, and nondisease-related eligibility criteria for transplantation in lymphoma; Introduction; Initial steps

Preparation for transplant center evaluationTransplant center evaluation; Post-evaluation review and final pretransplant process; References; Chapter 8: Stem cell mobilization in lymphoma patients; Introduction; Methods for mobilization; Stem cell collection and apheresis; Poor mobilizers and mobilization failure; Special populations; Complications; Future considerations; References; Chapter 9: Allogeneic hematopoietic stem cell transplantation for lymphoma: stem cell source, donor, and HLA matching; Historical perspective; Rationale for allogeneic transplantation; Stem cell source

Public Health